Utility of zinc protoporphyrin in management of whole blood donors

Deferral for low hemoglobin (Hb) increases the likelihood that donors do not return for future donations. Zinc protoporphyrin (ZPP) has been described as a sensitive marker of iron‐deficient erythropoiesis, before Hb decreases. It is a relatively cheap, rapid, and easy‐to‐perform measurement in a drop of whole blood. To assess the utility of ZPP measurement in donor management we examined whether ZPP and Hb levels among first‐time donors differ from repeat donors. We further explored whether ZPP increases over subsequent donations at a donor population level and whether increasing ZPP levels coincide with decreasing Hb levels and donor deferral.

[1]  G. Waeber,et al.  Iron and transfusion medicine. , 2013, Blood reviews.

[2]  Y. Vergouwe,et al.  Zinc protoporphyrin levels have added value in the prediction of low hemoglobin deferral in whole blood donors , 2013, Transfusion.

[3]  E. Lesaffre,et al.  Predicting hemoglobin levels in whole blood donors using transition models and mixed effects models , 2013, BMC Medical Research Methodology.

[4]  Y. Vergouwe,et al.  Development and validation of a prediction model for low hemoglobin deferral in a large cohort of whole blood donors , 2012, Transfusion.

[5]  Tessa Hillgrove,et al.  The impact of temporary deferral due to low hemoglobin: future return, time to return, and frequency of subsequent donation , 2011, Transfusion.

[6]  Y. Vergouwe,et al.  Prediction of low haemoglobin levels in whole blood donors , 2011, Vox sanguinis.

[7]  F. Boulton,et al.  Evidence‐based criteria for the care and selection of blood donors, with some comments on the relationship to blood supply, and emphasis on the management of donation‐induced iron depletion , 2008, Transfusion medicine.

[8]  A. Dewanji,et al.  Iron assessment tests: transferrin receptor vis-à-vis zinc protoporphyrin. , 2004, Clinical biochemistry.

[9]  J. Cook,et al.  The quantitative assessment of body iron. , 2003, Blood.

[10]  N. Milman,et al.  Iron status in Danish women, 1984–1994: a cohort comparison of changes in iron stores and the prevalence of iron deficiency and iron overload , 2002, European journal of haematology.

[11]  D K Stevenson,et al.  Zinc protoporphyrin: A metabolite with a mission. , 1999, Clinical chemistry.

[12]  J. Lindemans,et al.  Zinc protoporphyrin as screening test in female blood donors. , 1998, Clinical chemistry.

[13]  A. Reiter,et al.  Laboratory tests of iron status: correlation or common sense? , 1996, Clinical chemistry.

[14]  R. Hehlmann,et al.  Central role of zinc protoporphyrin in staging iron deficiency. , 1994, Clinical chemistry.

[15]  P. Grandjean,et al.  Screening with zinc protoporphyrin for iron deficiency in non-anemic female blood donors. , 1990, Clinical chemistry.

[16]  R. Labbé,et al.  Zinc Protoporphyrin Past, Present, and Future a , 1987, Annals of the New York Academy of Sciences.

[17]  P. Pisciotto,et al.  Evaluation of iron status in women identified by copper sulfate screening as ineligible to donate blood , 1987, Transfusion.

[18]  R. Schifman,et al.  RBC zinc protoporphyrin to screen blood donors for iron deficiency anemia. , 1982, JAMA.

[19]  A A Lamola,et al.  Zinc Protoporphyrin in the Erythrocytes of Patients with Lead Intoxication and Iron Deficiency Anemia , 1974, Science.